Matching articles for "dihydroergotamine"
Issue 1744 · December 22, 2025
A Dihydroergotamine Autoinjector (Brekiya) for Migraine

The FDA has approved Brekiya (Amneal), the first dihydroergotamine (DHE) autoinjector product. DHE has been available for IV, IM, SC and intranasal administration ( Trudhesa , and others). Like other…

Med Lett Drugs Ther. 2025 Dec 22; 67(1744):206-7 doi:10.58347/tml.2025.1744c
The FDA has approved Brekiya (Amneal), the first dihydroergotamine (DHE) autoinjector product. DHE has been available for IV, IM, SC and intranasal administration ( Trudhesa , and others). Like other parenteral DHE products, Brekiya is indicated for the acute treatment of migraine, with or without aura, and cluster headache in adults. It is not recommended for treatment of hemiplegic or basilar migraine. The FDA also recently approved the first intranasal powder formulation of DHE (Atzumi) for acute migraine treatment; it will be reviewed in a future issue.
Issue 1727 · April 28, 2025
A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine

The FDA has approved Symbravo (Axsome), an oral fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam and the 5-HT 1B/1D receptor agonist (triptan) rizatriptan ( Maxalt , and…

Med Lett Drugs Ther. 2025 Apr 28; 67(1727):68-70 doi:10.58347/tml.2025.1727b
The FDA has approved Symbravo (Axsome), an oral fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam and the 5-HT 1B/1D receptor agonist (triptan) rizatriptan ( Maxalt , and generics), for acute treatment of migraine with or without aura in adults. It is the second combination of an NSAID and a triptan to be approved for migraine treatment. An oral fixed-dose combination of sumatriptan and naproxen ( Treximet , and generics) is approved for use in patients ≥12 years old.
Issue 1681 · July 24, 2023
Zavegepant (Zavzpret) for Acute Treatment of Migraine

The FDA has approved zavegepant nasal spray ( Zavzpret – Pfizer) for acute treatment of migraine with or without aura in adults. Zavzpret is the first nasal spray formulation of a calcitonin gene-related…

Med Lett Drugs Ther. 2023 Jul 24; 65(1681):116-8 doi:10.58347/tml.2023.1681c
The FDA has approved zavegepant nasal spray ( Zavzpret – Pfizer) for acute treatment of migraine with or without aura in adults. Zavzpret is the first nasal spray formulation of a calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant") to become available in the US.
Issue 1678 · June 12, 2023 Free
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):89-96 doi:10.58347/tml.2023.1678a
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1640 · December 27, 2021
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine

The FDA has approved Trudhesa (Impel Neuropharma), a new dihydroergotamine nasal spray product, for acute treatment of migraine with or without aura in adults. Another dihydroergotamine nasal spray ( Migranal…

Med Lett Drugs Ther. 2021 Dec 27; 63(1640):204-7
The FDA has approved Trudhesa (Impel Neuropharma), a new dihydroergotamine nasal spray product, for acute treatment of migraine with or without aura in adults. Another dihydroergotamine nasal spray ( Migranal , and generics) has been available for many years for the same indication.
Issue 1608 · October 5, 2020
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2020 Oct 5; 62(1608):153-60
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1593 · March 9, 2020
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine

Lasmiditan ( Reyvow – Lilly), an oral serotonin (5-HT 1F ) receptor agonist, and ubrogepant ( Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by…

Med Lett Drugs Ther. 2020 Mar 9; 62(1593):35-9
Lasmiditan ( Reyvow – Lilly), an oral serotonin (5-HT 1F ) receptor agonist, and ubrogepant ( Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.
Issue 1514 · February 13, 2017
Drugs for Migraine

An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of…

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):27-32
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
Issue 136 · December 1, 2013
Drugs for Migraine

Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.

Treat Guidel Med Lett. 2013 Dec; 11(136):107-12
Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.
Issue 1057 · July 16, 1999
Amprenavir: A New HIV Protease Inhibitor

Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least…

Med Lett Drugs Ther. 1999 Jul 16; 41(1057):63-6
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Issue 1037 · October 9, 1998
New "Triptans" and Other Drugs for Migraine

Three new 5-HT1 receptors agonissts ('triptans') have been marketed recently for treatment of migraine. Some drugs for prevention of migraine are listed in the table on page 99. Treatment of migraine in the…

Med Lett Drugs Ther. 1998 Oct 9; 40(1037):97-100
Three new 5-HT1 receptors agonissts ('triptans') have been marketed recently for treatment of migraine. Some drugs for prevention of migraine are listed in the table on page 99. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 1021 · February 27, 1998
Zolmitriptan for Migraine

Zolmitriptan ( Zomig - Zeneca), a selective serotonin (5-HT1)-receptor agonist, is now available in the USA for oral treatment of migraine headache. Zomitriptan structurally resembles sumatriptan ( Imitrex -…

Med Lett Drugs Ther. 1998 Feb 27; 40(1021):27-8
Zolmitriptan ( Zomig - Zeneca), a selective serotonin (5-HT1)-receptor agonist, is now available in the USA for oral treatment of migraine headache. Zomitriptan structurally resembles sumatriptan ( Imitrex - Medical Letter 34:91, 1992). Drugs currently used for acute treatment of migraine include injectable, oral and nasal spray formulations of sumaptriptan, injectable dihydroergotamine, dihydroergotamine nasal spray, ergotamine tartrate alone or with caffeine, and various analgesics. Anoterh 5-HT1-receptor agonist, naratriptan ( Amerge - Gaxo Wellcome), has been approved by the FDA but has not been marketed yet.
Issue 1003 · June 20, 1997
Midodrine for Orthostatic Hypotension

Midodrine hydrochloride ( ProAmatine - Roberts), an alpha1-selective adrenergic agonist, is now available for treatment of severe symptomatic orthostatic hypotension. Other treatments for this condition…

Med Lett Drugs Ther. 1997 Jun 20; 39(1003):59-60
Midodrine hydrochloride ( ProAmatine - Roberts), an alpha1-selective adrenergic agonist, is now available for treatment of severe symptomatic orthostatic hypotension. Other treatments for this condition include other sympathomimetics, constrictive garments, erythropoietin ( Epogen ; Procrit) and fludrocortisone with salt (D Robertson and TL Davis, Neurology, 45 suppl 5: S26, 1995).
Issue 943 · March 3, 1995
Drugs for Migraine

Drugs are used both to prevent and treat migraine symptoms. The effectiveness of such use can be difficult to evaluate, even with double-blind controlled trials, because migraine is episodic, response to…

Med Lett Drugs Ther. 1995 Mar 3; 37(943):17-20
Drugs are used both to prevent and treat migraine symptoms. The effectiveness of such use can be difficult to evaluate, even with double-blind controlled trials, because migraine is episodic, response to placebo is frequent, and patients vary in response to a given agent (KMA Welch, N Engl J Med, 329:1476, 1993; SD Silberstein and RB Lipton, Neurology, 44 suppl 7:S6, Oct 1994).
Issue 880 · October 2, 1992
Sumatriptan for Migraine

Sumatriptan (soo ma trip' tan; Imitrex - Glaxo), a serotonin (5-HT) agonist, is now available in Canada and may soon be available in the USA for oral or parenteral treatment of migraine headache. The…

Med Lett Drugs Ther. 1992 Oct 2; 34(880):91-3
Sumatriptan (soo ma trip' tan; Imitrex - Glaxo), a serotonin (5-HT) agonist, is now available in Canada and may soon be available in the USA for oral or parenteral treatment of migraine headache. The parenteral formulation is designed for patients to inject themselves subcutaneously. Sumatriptan is not recommended for prophylactic use.